- Poster presentation
- Open Access
Low reduction of HCV-RNA level at week 4 in HIV-1 infected patients with acute HCV Infection
© Vincent et al; licensee BioMed Central Ltd. 2012
- Published: 25 May 2012
- Sustained Virological Response
- Acute Hepatitis
- Virological Response
- 2log Reduction
- Spontaneous Reduction
The epidemic of acute Hepatitis C-virus infection (AHC) is an on-going issue, especially among MSM patients. Spontaneous HCV clearance rates have been estimated to be between 5-40%, with lower rates among HIV-1 co-infected patients. High rates of sustained virological response have been observed (60-80%) when patients are treated within 24 weeks of AHC diagnosis. Moreover, a spontaneous 2log reduction in HCV-RNA might be a good predictor of spontaneous HCV-RNA clearance in HIV-1 co-infected patients. The aim of this study is to analyse the incidence of 2-log-HCV-RNA spontaneous reduction in AHC in HIV-1 infected patients.
We reviewed medical files of 930 HIV-1-infected patients from our Reference Centre. All patients diagnosed with AHC in 2010-2011 were included. Diagnosis of AHC was based on seroconversion and ALT elevation. HCV-RNA PCR data was collected at time of and on week 4 after diagnosis.
Demographic data (data shown in numbers (%) or median)
Transmission risk-factor; MSM
CD4-cells count (median)
HIV-RNA (copies/mL) (median)
HCV-RNA To (copies/mL)
HCV-RNA T+4weeks (copies/mL)
- 2 log at T+ 4w
- 2 log at T+ 4w according to genotype
3 (100%) genotype 1a / 0 genotype 4
AST (IU/L) T0 (median)
ALT (IU/L) T0 (median)
ALT (IU/L) T+4w (median)
Although completed on a small number of patients, this audit suggests that only a low proportion (33%) of HIV-1 infected patients presenting with AHC will meet a favourable 2log-HCV-RNA-drop criteria. This is slightly lower than rates reported by NEAT (i.e. 48%). It implies that these co-infected patients should benefit from a close follow-up in order to start treatment within 24 weeks of AHC diagnosis, whenever it is needed and available.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.